Business
Medicenna Reports First Quarter Fiscal 2020 Financial Results
Medicenna Reports First Quarter Fiscal 2020 Financial Results Canada NewsWire TO...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna Reports First Quarter Fiscal 2020 Financial Results\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and HOUSTON, Aug. 9, 2019\n\n\n\nTORONTO and HOUSTON, Aug. 9, 2019 /CNW/ - Medicenna Therapeutics Corp. (\"Medicenna\" or the \"Company\") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, today reported financial results for the three months ended June 30, 2019. The Company's fiscal Q1 2020 interim financial statements and MD&A will be available on SEDAR.\n\"We are delighted with the exceptional milestones that we have accomplished during the first fiscal quarter of 2020, including very positive interim Phase 2b results for MDNA55 in recurrent Glioblastoma (rGBM) patients and selection of MDNA19 as our second immuno-oncology clinical candidate,\" said Dr. Fahar Merchant, President and Chief Executive Officer, Medicenna Therapeutics. \"Both our pipeline and the Company overall are in a strong position as we move closer to our planned End of Phase 2 meeting for MDNA55 with the US FDA later this year.\"\nThe following are the achievements and highlights for the quarter ending June 30, 2019, through to the date hereof:\nFollowing quarter end, on July 31, 2019, Medicenna announced the selection of MDNA19 (formerly, MDNA109-LA1) as its second immuno-oncology clinical candidate for the treatment of cancer. MDNA19 is a best-in-class long-acting IL-2 developed from Medicenna's Superkine platform that has shown unique ability to selectively stimulate cancer killing immune cells without the limitations seen with other long-acting IL-2 programs. Medicenna expects to begin clinical trials with MDNA19 in 2020. Following quarter end, on July 9, 2019 Medicenna announced that it had received US$1,915,372 (approximately CDN $2.5M) from the Cancer Prevention and Research Institute of Texas (CPRIT). On June 26, 2019, Medicenna reported pre-clinical data on MDNA55 which showed promising results in ovarian cancer models. On June 20, 2019, Medicenna presented a poster entitled \"Engineering a long-acting CD122 biased ...